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ABSTRACT 
 
Background  
It is well established that people with IBS have higher levels of anxiety and depression 
compared to controls. However, the role of these as risk factors is less clearly established. 
The aims of this systematic review were to investigate 1) whether anxiety and/or depression 
predict IBS onset 2) the size of the relative risk of anxiety versus depression in IBS onset. 
Sub-group analyses explored if methodological factors affected the overall findings.   
Methods   
Prospective cohort or case-control studies were included if they 1) focused on the 
development of IBS in population based or gastroenteritis cohorts 2) explored the effects of 
anxiety and/or depression at baseline as predictors of IBS onset at a future point. Eleven 
studies were included of which 8 recruited participants with a gastrointestinal infection. Meta-
analyses were conducted. 
Results  
The risk of developing IBS was double for anxiety cases at baseline compared to those who 
were not: RR 2.38, 95% CI 1.58-3.60. Similar results were found for depression: RR 2.06, 
95% CI 1.44-2.96. Anxiety and depression seemed to play a stronger role in IBS onset in 
individuals with a gastrointestinal infection although this could be attributed to other 
differences in methodology, such as use of diagnostic interviews rather than self-report. 
Conclusions 
The findings suggest that self-reported anxiety and depression provide a twofold risk for IBS 
onset. There is less support for the role of anxiety or depressive disorder diagnosed using 
clinical interview. These findings may have implications for the development of interventions 
focused on IBS prevention and treatment.  
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INTRODUCTION 
Irritable Bowel Syndrome (IBS) is a chronic functional gastrointestinal disorder associated 
with abdominal pain, bloating and change in bowel habit, with either predominantly diarrhoea, 
constipation or a combination of both (Spiller et al. 2007). A clinical diagnosis of IBS is based 
on the identification of positive symptoms through diagnostic criteria and the exclusion of 
organic diseases and alarm symptoms, such as unexplained weight loss and rectal bleeding 
(Manning et al. 1978; Drossman, 2006).  
The prevalence of IBS ranges between 10 – 25% in community samples and it affects around 
11% of the global population (Canavan et al. 2014; Lovell & Ford 2012). IBS has significant 
financial consequences, with direct costs per patient ranging from $1,562 to $7,547 per year, 
and indirect costs from $791 to $7,737 per year (Nellesen et al. 2013). Humanistic burdens of 
IBS include a negative impact on quality of life, social functioning and time off work (Spiller et 
al. 2007). Treatment for IBS relies on lifestyle advice, and medical and psychological 
therapies (Akehurst & Kaltenthaler 2001;Talley et al. 2015).  
Current conceptualisations of IBS include the biopsychosocial model, which acknowledges 
the two-way communication between mind and body (Engel, 1980; Drossman, 1998; Tanaka 
et al. 2011). Psychological and social factors interact with physiological factors (e.g. intestinal 
inflammation, altered motility and bacterial flora) through the bidirectional communication 
between the central nervous system and the enteric nervous system (Jones et al. 2006; 
Surdea-Blaga et al. 2012). More specifically, the biopsychosocial model suggests that 
biological and psychosocial predisposing factors in early life, such as genetics, heredity, 
trauma, and parental illness behaviours, increase people’s susceptibility to develop IBS. 
Precipitating factors (e.g. lack of social support, stressful life events, gut infection) can closely 
precede and trigger IBS. Perpetuating factors, such as anxiety, depression, negative 
perceptions of symptoms and illness behaviours contribute to the maintenance of symptoms 
over time (Hauser et al. 2014; Deary et al. 2007). Anxiety and depression are usually 
considered perpetuating factors of IBS symptoms but it is also possible that they act as 
predisposing or precipitating factors of IBS alongside other risk factors, such as an acute 
gastrointestinal (GI) infection (Stermer et al. 2006; Hamilton et al. 2009; Marshall et al. 2010; 
Spiller & Lam 2012).  
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Studies suggest that around 5% to 32% of patients develop IBS after GI infections (Thabane 
& Marshall, 2009) but this percentage may be higher as GI infections tend to be 
underreported by patients. It is still not clear whether post-infectious IBS (PI-IBS) is a different 
sub-group of patients suffering from IBS (Sundin et al. 2015). Research has found that a 
history of previous treatment of anxiety/depression is less correlated with PI-IBS than non PI-
IBS (Dunlop et al. 2003). Therefore, exploring the role of anxiety and depression as risk 
factors of IBS in both GI samples and population based studies may contribute to 
understanding sub-group differences in IBS. 
Although recent literature acknowledges the interplay between mind and body and describes 
the potential mechanisms underlying IBS pathophysiology (Stasi et al. 2012; Mayer et al. 
2015), in clinical practice some doctors still conceive IBS as a sole somatisation of anxiety 
and depression (Dixon-Woods & Critchley, 2000; Bijkerk et al. 2003; Lacy et al. 2006). 
Indeed, patients feel that some doctors, because of their psychological view of the syndrome, 
do not take their symptoms seriously (Kennedy et al. 2003). 
It is well established that individuals with IBS have higher levels of anxiety and depression 
compared to healthy controls (Henningsen et al. 2003; Fond et al. 2014). Cross-sectional 
analyses report a positive association between IBS symptoms and anxiety and depression 
(Masand et al. 1995; Mykletun et al. 2010; Phillips et al. 2013). However, these analyses 
cannot determine whether anxiety and depression increase the risk of developing IBS.  
The purpose of this paper was to systematically review prospective studies investigating 
anxiety and depression as risk factors for the onset of IBS and to employ meta-analysis to 
understand the size of the effects. Quality assessment of studies was conducted to help 
understand any inconsistencies in data across studies. The research questions were: 1) are 
anxiety and/or depression significant predictors IBS onset? (i.e. do they increase the risk of 
developing IBS?) 2) what is the size of the relative risk of anxiety and depression in the onset 
of IBS? Sub-group analyses were also planned to explore if (a) population based vs GI 
samples (b) type of anxiety/depression measurements (c) IBS diagnostic criteria used and (d) 
length of follow-ups affected the overall findings. The length of follow-up can help to elucidate 
the temporal effect of anxiety/depression in the development of IBS by studying their role as 
potential precipitating factors in the short and long term.  
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METHODS 
The findings of this systematic review are reported in accordance with Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses guidelines and Guidelines for Meta-
Analyses and Systematic Reviews of Observational Studies. The process followed an a priori 
established protocol. 
 
Search strategy and study selection 
Electronic databases (MEDLINE - Ebsco, EMBASE - Ovid, Web of Science -  ISI Web of 
Knowledge, CINAHL – Ebsco, and PsychINFO - Ebsco) were searched systematically for 
studies published between database start to the 18th of March 2015 by two authors (AS and 
PW). The reference lists of all eligible studies were also hand searched to identify further 
potential studies. MeSH terms relevant to anxiety, depression and Irritable Bowel Syndrome 
were used in the search. The search strategies for each specific database are shown in 
Appendix 1.  
 
Study selection 
Studies were included if they met all the following criteria: 1) prospective cohort or case-
control studies that investigated anxiety and/or depression measured at baseline and their 
relationship with a new diagnosis of IBS at a future time point 2) population based studies or 
studies with individuals with a GI infection aged 16 years or over 3) studies that assessed 
anxiety and depression through validated psychometric measures or a structured clinical 
interview 4) studies that established a diagnosis of IBS at the endpoint (at least 3 months 
post-baseline) based on: published diagnostic criteria, adapted published diagnostic criteria 
or a multi-item symptom questionnaire.  
Exclusion criteria for this review were: articles that were not empirical studies; dissertation 
and conference abstracts; studies that included a treatment condition; studies that included 
IBS patients as a sub-group of a larger sample, where the results were not presented 
separately from the other participants; sample with a primary GI diagnosis that was not IBS; 
cross-sectional studies. Retrospective studies excluded from this review were defined as: 1) 
studies that assessed anxiety and/or depression pre-IBS onset when the participants already 
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had IBS 2) studies that assessed anxiety and/or depression levels longer than 4 months after 
the onset of the GI infection 3) studies that retrospectively collected data from a database 
where the measures of anxiety/depression and the assessment of IBS were not standardised.  
Two authors (AS and PW) independently screened titles and abstracts for inclusion. 
Disagreements occurred for 10 out of 5454 abstracts screened (0.2%). A total of 93 full-texts 
were assessed for eligibility. Uncertainties regarding inclusion of studies were resolved 
through discussions between RMM, AS and PW.  
 
Data extraction 
Data extraction was conducted independently by two authors (AS and PW). Attempts were 
made to contact the authors by email where insufficient data were reported. Data were 
extracted from the included studies using a predefined Excel electronic template (see 
Appendix 2 for the variables extracted). Any discrepancies in data extraction were discussed 
between RMM, AS and PW. 
 
Quality assessment 
The methodological quality of the included studies was assessed independently by two 
authors (AS and SW) using an adapted version of the Black and Downs scale (Downs & 
Black, 1998) for observational studies. The adapted scale had an overall score of 29 points 
for the studies that included participants with gastroenteritis and an overall score of 27 for 
those studies with non-GI samples (See Appendix 3 for a detailed description of the scale and 
scoring).  
Inter-rater agreement for categorical scorings on each item of the adapted scale was 
assessed using Cohen’s Kappa. An intraclass correlation coefficient was calculated to assess 
inter-rater agreement for the entire scale (i.e. using the overall numerical scores). Statistical 
analyses were performed using SPSS version 22.0 (IBM, Armonk, New York). 
 
Quantitative synthesis 
To ascertain whether anxiety and/or depression increased the risk of developing IBS, we 
used the metan command in STATA 11 (StataCorp, College Station, TX, USA) to perform 
meta-analyses on relative risks as the effect measure. We derived the summary estimate 
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using a random effects model (DerSimonian and Laird) with the estimate of heterogeneity 
being taken from the Mantel–Haenszel model (Sterne et al. 2001; Harris et al. 2008). Ninety-
five per cent confidence intervals (95% CI) were reported for each study’s relative risk and the 
pooled relative risk. 
The heterogeneity was evaluated using the I2 statistic, which provides a percentage of the 
variation attributable to the degree of differences between studies caused by factors other 
than sampling error. We used the following categories to interpret the levels of heterogeneity: 
low between 15%-50%, moderate between 50-75% and high for 75% or over (Higgins et al. 
2003). Sub-group analyses were conducted to explore the potential sources of heterogeneity 
between studies: studies including individuals with a GI infection vs non-GI samples, 
anxiety/depression assessment, IBS assessment and follow-up period. 
Since the studies used different cut-offs to determine anxiety and depression caseness at 
baseline, we also conducted meta-analyses of continuous measures of anxiety/depression if 
enough data were reported or provided by the authors. Additional studies providing only 
continuous data were also included in this analysis. The metan command was used to 
calculate standardised mean differences by the method of Cohen. Random effect models 
using the DerSimonian and Laird method were selected. Publication bias was assessed using 
funnel plots and the Egger test (Sterne & Harbord, 2004).  
 
RESULTS 
Search strategy and study selection 
Eleven papers were included in this systematic review (see Figure 1 for the flow diagram of 
systematic literature searches). 
INSERT Figure 1 approximately here 
 
Overview of studies 
Eight of the 11 studies recruited participants with a GI infection at baseline. From these 8 
studies, two recruited hospitalised patients. The remaining three were population-based 
studies (see Table 1 for details of the included studies and Appendix 4 for details of the 
baseline characteristics of the each study). 
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INSERT Table 1 approximately here 
 
Assessment of anxiety and depression 
Nine studies used the Hospital Anxiety and Depression Scale (HADS) (Zigmond & Snaith, 
1983) at baseline to measure the levels of anxiety and depression (see details in Table 1). 
Nielsen et al. (2014) used an adapted version of the HADS scale, which consisted of 6 
depression related items and 6 anxiety related items. Each item score ranged between 0 and 
3 and the overall score for each sub-scale ranged from 0 to 18. Table 1 shows the cut-off 
scores adopted in each study for cases of anxiety and depression. Koloski et al. (2012) used 
14 items from the Delusion Symptom States Inventory (DSSI) (Class I, Dysthymic disorders) 
to measure anxiety and depression (Bedford & Foulds, 1977). Talley et al. (2001) was the 
only study to use a defined mental health diagnosis using a modified version of the Diagnostic 
Interview Schedule (Robin et al. 1981).  
 
Assessment of methodological quality 
All the studies were of moderate quality except for Gwee et al. (1999) which had good quality 
(see Table 1 and Appendix 5 for the detailed scores). The quality assessment found that 
some studies presented common limitations: they did not report enough information to 
determine the external validity of the study; they did not apply a rigorous assessment to 
exclude participants with IBS at baseline; they failed to conduct a power calculation; nor did 
they control adequately for potential confounders.  
There was complete agreement between the two raters when scoring the items of the scale 
across studies except for minor discrepancies on two items: 7 (item 9 from the original scale) 
and 17 (adapted item for this review). Cohen’s Kappa was 0.800 (standard error=0.186, 
p=0.01) for item 7 and 0.831 (standard error=0.156, p=0.000) for item 17, which indicated 
substantial agreement. The intraclass correlation coefficient of the adapted scale was 0.998 
(95% CI 0.991-0.999, p=0.000), which showed high reliability. After discussion, full agreement 
was reached between the two raters and minor wording amendments were implemented to 
item 17. 
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Quantitative synthesis findings 
Anxiety - categorical  
Seven studies were included in this meta-analysis with a total sample of 4810 subjects. Three 
hundred and twenty five of these developed IBS at the end point and 4485 did not develop 
IBS (see Appendix 6 for details of the data extracted from each study). The length of the 
follow-ups ranged from 3 months to 8 years with a median of 6 months. Five studies recruited 
participants with a GI infection (Gwee et al. 1996; Borgaonkar et al. 2006; Nielsen et al. 2014; 
Moss-Morris & Spence 2006; Wouters et al. 2015) and 2 were population based studies 
(Talley et al. 2001; Nicholl et al. 2008) (see Table 1 for characteristics of the included 
studies). 
The overall risk of developing IBS at follow-up was more than double for those subjects who 
met the criteria of anxiety caseness at baseline compared to those who did not (RR 2.38, 
95% CI 1.58-3.60). The I2 showed moderate heterogeneity between studies (70.9%) 
(p=0.002) (see Figure 2 for the forest plot). 
 
INSERT Figure 2 approximately here 
 
Figure 2 shows that participants who met the criteria for anxiety caseness at baseline in the 
Wouters et al. (2015) study had five times the risk of developing IBS at the end point (RR 
5.04 95% CI 3.01-8.45). Interestingly, this is the only study that recruited participants during 
or soon after an epidemic outbreak of infectious gastroenteritis. The inhabitants were 
informed about being exposed to the contaminated water by the local authorities, which may 
have increased the anxiety levels of this specific sample during the recruitment phase. 
Furthermore, the Gwee et al. (1996) study showed the second highest risk of developing IBS 
(RR 3.69, 95% CI 1.97-6.90). Participants were recruited whilst hospitalised due to a GI 
infection and this may be the reason for the higher risk compared to most studies.  
In contrast to the overall effect, two studies found that anxiety decreased the risk of IBS 
although these results were not statistically significant. Talley et al. (2001) showed a 26% 
reduced risk of developing IBS for the baseline anxiety cases (RR 0.74, 95% CI 0.31-1.76). 
This is the only study that used an adapted clinical structured interview schedule to assess 
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anxiety disorders and very long-term follow-up of 8 years. However, this study did not report if 
they excluded individuals with IBS at baseline. Borgaonkar et al. (2006) showed a 10% 
decreased risk of IBS onset for those participants with anxiety caseness at baseline (RR 0.90, 
95% CI 0.18-4.48). In terms of the methodology, the mean time between the GI infection and 
the baseline measurements of anxiety was 46+-26 days. This suggests that for some 
participants anxiety was measured post-infection rather than at baseline. 
Sensitivity analysis 
We conducted the same meta-analysis for Anxiety - categorical excluding Talley et al. (2001) 
(ROME criteria, episodic anxiety) as the methodology and follow-up period were distinctly 
different from the other studies. The effect of anxiety was slightly stronger (RR 2.80, 95% CI 
1.99-3.94). According to the I2, the heterogeneity between studies dropped from 70.9% to 
56% (moderate heterogeneity) (p=0.045). 
We also conducted the same meta-analysis excluding Borgaonkar et al. (2006) as some of 
their participants completed the baseline measures post-infection. The relative risk of anxiety 
was slightly stronger (RR 2.51, 95% CI 1.66-3.82) and the heterogeneity remained practically 
stable (73.3%, p=0.002). 
In summary, our meta-analysis showed that the overall risk of developing IBS at follow-up 
was double for those subjects who met the criteria for anxiety caseness at baseline compared 
to those who did not. The different sensitivity analyses showed similar findings. 
 
Depression - categorical  
Eight studies were included in this meta-analysis with a total sample of 5007 subjects. From 
these, 342 developed IBS at the end point and 4665 did not develop IBS. See Appendix 7 for 
details of the data extracted. The length of the follow-up ranged from 3 months to 8 years, 
with a median of 6 months. Six studies recruited participants with a GI infection (Gwee et al. 
1996; Borgaonkar et al. 2006; Parry et al. 2005; Nielsen et al. 2014; Moss-Morris & Spence, 
2006; Wouters et al. 2015) and 2 were population based studies (Nicholl et al. 2008; Talley et 
al. 2001) (see Table 1 for characteristics of the included studies). 
The overall risk of developing IBS at follow-up was double for those subjects who met the 
criteria for depression caseness at baseline compared to those who did not (RR 2.06, 95% CI 
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1.44-2.96). The I2 showed low heterogeneity between studies (48.40%) (p=0.06) (see Figure 
3 for the forest plot). 
INSERT Figure 3 here 
 
As shown in Figure 3, the baseline depression cases in Parry et al. (2005) presented almost 
six times the risk of developing IBS (RR 5.57, 95% CI 2.79-11.16). This very high risk is 
probably due to the fact that 2 out of 2 participants with depression caseness at baseline 
developed IBS at the endpoint compared to 14 out of 96 in the non-depression group.  
On the other hand, in Borgaonkar et al. (2006), the participants who met the criteria for 
depression caseness at baseline had their risk of developing IBS reduced by 45% (RR 0.55, 
95% CI 0.03-9.26) although this was not statistically significant. The wide CI are probably 
explained by the fact that 0 out of the 16 depression cases at baseline developed IBS. As 
described above, the measurements of baseline depression were collected post-infection for 
some participants.  
Sensitivity analysis 
We conducted the same meta-analysis for Depression - categorical excluding Talley et al. 
(2001) (ROME criteria, episodic depression). The effect of depression was slightly stronger 
(RR 2.23, 95% CI 1.53-3.26). However, the heterogeneity remained practically stable from 
48.4% to 46.1% (p=0.085). The aforementioned drop in I2 for anxiety was due to the non-
overlap of the CI for the Talley study with the pooled effect. However, the CI does overlap for 
depression and this is why the I2 percentage does not change. 
We conducted the same meta-analysis excluding Parry et al. (2005). The pooled RR still 
shows that depression is a predictor of IBS onset (RR 1.82, 95% CI 1.41-2.35). More 
importantly, the I2 drops from 48.4% to 0% (p = 0.739). 
We also conducted the same meta-analysis excluding Borgaonkar et al. (2006) as some of 
their participants completed the baseline measures post-infection. The relative risk of 
depression remained practically stable (RR 2.11, 95% CI 1.46-3.04) as well as the 
heterogeneity (52.2%, p=0.051). 
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In summary, our meta-analysis showed that the overall risk of developing IBS at follow-up 
was double for those subjects who met the criteria for depression caseness at baseline 
compared to those who did not. The different sensitivity analyses showed similar findings. 
 
Anxiety - continuous  
Five studies provided continuous data for anxiety. The Koloski et al. (2012) study was the 
only one not included in the previous meta-analyses where anxiety and depression were 
treated as categorical variables (see Appendix 8 for details of the data extracted and the 
forest plot). The results showed that there was a moderate effect of baseline anxiety as a 
predictor of IBS onset at follow-up. The pooled standardised mean difference was 0.62, 95% 
CI 0.39-0.84. The I2 (51.00%) showed moderate heterogeneity between studies (p= 0.09). 
 
Depression - continuous 
Four studies provided continuous data for depression (see Appendix 9 for details of the data 
extracted and the forest plot). The results showed that there was a small effect of baseline 
depression as a predictor of IBS onset at follow-up. The pooled standardised mean difference 
was 0.32, 95% CI 0.16- 0.47. The I2 (7.6%) showed low heterogeneity between studies 
(p=0.36).  
 
Sub-group analyses  
GI infection vs no-GI infection 
For both anxiety and depression, the risk of developing IBS was higher in those studies that 
recruited individuals with a GI infection at baseline compared to population based studies 
(see Table 2 for detailed results). These results may be affected by the methodological 
differences of one of the no-GI infection studies (Talley et al. 2001), such as the use of a 
clinical structured interview to diagnose anxiety/depression and a longer follow-up length. 
 
INSERT Table 2 approximately here 
 
Type of anxiety/depression assessment  
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For both anxiety and depression, the risk of developing IBS was estimated to be higher when 
pooling studies that used the HADS compared to the one study that used a clinical diagnostic 
interview schedule (see Table 2 for detailed results). While this difference is not statistically 
reliable, it does suggest an interesting avenue for future research. 
 
Type of IBS diagnostic criteria and follow-up length 
Our sub-group analysis did not show clear patterns in terms of the IBS diagnostic criteria 
(ROME vs non-ROME) and length of the follow-ups (see Appendices 10 and 11 for forest 
plots). 
 
Publication bias 
Based on the funnel plots and the non-significant Egger test results for both anxiety (p=0.278) 
and depression (p=0.339), we concluded that there was no small-study effects (see 
Appendices 12 and 13 for detailed results). 
 
 
DISCUSSION 
 
The main purpose of this systematic review was to ascertain whether prior anxiety or 
depression raise the risk of developing IBS.  
 
Summary of results  
Our meta-analyses showed that the overall risk of developing IBS at follow-up was double for 
those subjects who met the criteria for anxiety caseness at baseline compared to those who 
did not, with similar results for those subjects who were depression cases at baseline. 
When treated as continuous variables, the results showed that there was a moderate effect of 
baseline anxiety and a small effect of baseline depression as predictors of IBS onset at 
follow-up. However, these two analyses included 5 and 4 studies respectively and the results 
are only exploratory. 
The sub-group analyses for anxiety and depression treated as categorical variables showed 
two findings: 1) for both anxiety and depression, the risk of developing IBS was higher in 
those studies that recruited individuals with a GI infection at baseline and 2) for both anxiety 
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and depression, the risk of developing IBS was higher in those studies that used the HADS 
compared to the one study that used a clinical diagnostic interview; however, this comparison 
between one study and the rest is not statistically reliable and needs to be confirmed in 
further studies using a psychiatric diagnosis. 
 
PI-IBS vs non PI-IBS cohorts 
Our sub-group analyses suggested that both anxiety and depression played a stronger role in 
the onset of IBS in individuals with a GI infection at baseline compared to population based 
studies. This could be attributed to other differences in methodology such as use of 
diagnostic interviews rather than self-report measures of depression and anxiety. However, it 
is possible that psychological factors have either a direct or indirect effect on the 
pathophysiology of PI-IBS. Wouters et al. (2015) proposed that anxiety may raise the risk of 
PI-IBS by directly increasing the susceptibility to develop a GI infection. Future research 
should move beyond animal models and explore the neurobiological mechanisms of the 
potential effects of depressive and anxious mood in the development of PI-IBS. 
It could also be argued that the severity of the infection may cause or aggravate distress 
during the gastroenteritis. Nevertheless, these results are relevant as they suggest that those 
individuals who present with anxious or depressive mood during a GI infection are at 
increased risk of developing PI-IBS at a future time point. Therefore, the identification of these 
risk factors during the acute phase may be important to decrease the chances of developing 
IBS in a specific group of patients. Though most of the included studies had GI samples, this 
does not rule out that psychological distress plays a role in IBS more generally. Our meta-
analyses showed that baseline anxiety and depression were risk factors of IBS onset at a 
future time point in two out of three population based studies (Nicholl et al. 2008; Koloski et 
al. 2012) (See Figures 2 and 3 and Appendices 8 and 9 for detailed results). The only study 
that found conflicting results for anxiety presented substantial methodological differences: 
they used a psychiatric diagnosis of anxiety/depression and did not specify whether 
participants with IBS were excluded at baseline (Talley et al. 2001). Thus, future cohort 
studies should assess anxiety and depression through psychiatric diagnostic criteria as well 
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and implement strict exclusion/inclusion criteria in order to confirm the role of 
anxiety/depression as risk factors in IBS (not PI-IBS).  
 
Psychological distress vs psychiatric diagnosis 
Nine out of the eleven studies included in this review used the HADS to measure anxiety and 
depression levels (see Table 1 for details). Norton et al. (2013) found that, even though the 
HADS addresses the concepts of autonomic arousal (anxiety) and anhedonia (depression), it 
has a general psychological distress factor which represents a shared variance between 
symptoms of depression and anxiety. This suggests that the HADS should be best used as a 
total score measuring general psychological distress rather than two separate precise 
measures of anxiety and depression. 
In relation to our meta-analyses data, this suggests that generalised psychological distress is 
a predictor of IBS onset rather than specific diagnoses of anxiety and depression. Indeed, the 
mean and SD of the HAD anxiety and depression sub-scales of the included studies were 
within normal or borderline abnormal ranges (see Appendix 14 for figures).  
These findings highlight the potential importance of psychological distress, rather than 
psychopathology per se, in the development of IBS. Recent studies have attempted to explain 
the possible pathophysiological mechanisms linking distress to IBS through dysregulation of 
the brain-gut axis (Mayer & Tillisch, 2011). The autonomic nervous system response to stress 
or distress includes the release of corticotrophin releasing factor (CRF) via the hypothalamic-
pituitary-adrenal-axis, which can 1) stimulate colonic motility via CRF1 receptors 2) increase 
the activation of mast cells in the colonic mucosa, which in turn can enhance both abdominal 
pain and mucosal permeability and 3) promote low-grade inflammation/immune activation via 
cytokine stimulation, particularly during a GI infection (Stasi et al. 2012; Spiller & Lam, 2012). 
Thus, psychosocial distress can directly or indirectly affect motility, abdominal pain, secretion 
and immune function of the bowels as well as the perception of visceral stimuli.  
Future research should focus on the neurobiological mechanisms underlying IBS onset and 
the potential role that abnormalities in central pain processing and cognitive functioning play 
in IBS onset as these are mediated by anxiety and depression (Kennedy et al. 2012). 
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Anxiety and depression alongside other risk factors 
Although our meta-analyses findings suggest that anxiety and depression are significant risk 
factors of IBS (i.e. two-fold increased risk), many of the included studies found that anxiety 
and depression were only two of a range of risk factors increasing the chances of developing 
IBS. Several of these studies explored the roles of other psychological factors including life 
events, perceived stress, negative illness beliefs, somatisation (tendency to report general 
somatic symptoms), hypochondriasis, illness behaviours (characterised mainly by avoidance 
behaviours, health seeking behaviours and all-or-nothing behaviours) in the onset of IBS 
(Gwee et al. 1999; Parry et al. 2005; Moss-Morris & Spence, 2006; Borgaonkar et al. 2006, 
Spence & Moss-Morris, 2007; Nicholl et al. 2008; Wouters et al. 2015). There was insufficient 
commonality across studies to incorporate these within a meta-analysis. However, it is worth 
noting that in multivariate analyses considering anxiety and depression alongside these 
factors as well as biological factors, distressed mood was only one of many risk factors for 
IBS. In some instances, the significant relationship between anxiety and depression and IBS 
onset disappeared (Gwee et al. 1999; Borgaonkar et al. 2006; Nicholl et al. 2008; Wouters et 
al. 2015). 
One of the included studies found that exposure to two or more of the following factors 
identified 80.2% of all participants developing IBS: scoring in the highest third of the HAD 
Anxiety sub-scale and Estimated Sleep Problems Scale, and in the highest two-thirds of the 
Somatic Symptoms Checklist and Illness Behaviour Scale (Nicholl et al. 2008). Taken 
together, these findings argue against a simple somatisation hypothesis, and highlight that 
multiple factors in addition to baseline distress influence the development of IBS. 
These findings are in line with the biopsychosocial model, which suggests that genetics and 
environmental factors in early life may predispose to IBS and that cognitive, behavioural, 
emotional and biological/physiological factors (including GI infection) interact to precipitate 
and perpetuate symptoms and contribute to disability (Engel, 1980). 
 
Implications for future studies  
In order to understand in more depth the role of anxiety and depression in IBS onset, it is 
essential to conduct more prospective studies with individuals free of IBS at baseline with 
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large sample sizes ensuring a rigorous and standarised assessment of 1) IBS at baseline (to 
exclude participants with IBS) and at the endpoint 2) psychological distress and psychiatric 
diagnosis of anxiety/depression 3) a well-defined multifactorial set of biopsychosocial 
predictors, which are tied in with specific theories of IBS aetiology. Furthermore, several long-
term follow-ups across the same sample would help to determine the incidence and 
prevalence of IBS within the same cohort at different time points, as well as help to 
distinguish between factors that predispose or precipitate the condition and those that 
perpetuate the symptoms. The clinical exclusion of organic diseases through adequate 
medical tests and assessments would also strengthen the methodological quality of research. 
Eight out of the 11 included studies were conducted with individuals with a GI infection and 
our findings may be more representative of PI-IBS and the IBS diarrhoea sub-type. Ideally, 
future longitudinal studies would measure anxiety and depression before GI infection onset in 
order to explore their role as risk factors of PI-IBS rather than possible comorbidities that 
arise due to the presence of GI symptoms. However, studies such as these are extremely 
costly as they rely on broad population based samples. For those recruiting a GI infectious 
cohort, anxiety and depression should be assessed as closely as possible to the GI infection 
onset or during the acute phase. As some studies included in this review reported that the 
mean duration of acute symptoms ranged between 7.3 and 12.4 days from onset in the group 
that developed IBS, baseline assessments should ideally be conducted within this 1-3 week 
window. More population based studies are needed to confirm the role of anxiety and 
depression as predictors of IBS onset in non PI-IBS.  
 
Implications for clinical practice 
Promoting awareness about the potential role that anxiety and depression (or general 
distress) have on the development of IBS, in combination with biological factors and unhelpful 
illness cognitions and behaviours, may help to reduce the incidence of IBS onset in high risk 
individuals (e.g. severe symptoms during a gastroenteritis, chronic abdominal pain, recent 
adverse life events).  
Although the results suggest that targeting distress in early interventions may be helpful, 
psychotherapies that are designed to target primary anxiety and depressive disorders may 
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not be the best treatments for IBS. Rather, treatments should focus on a range of factors 
which may perpetuate the syndrome including IBS related beliefs and coping behaviours, 
alongside negative mood. The language used by clinicians and health professionals to 
promote preventative psychological interventions would benefit from incorporating the notion 
that although distress (feeling anxious and/or depressed) increases the risk of developing 
IBS, this does not suggest patients have a mental health disorder rather than IBS. Distress, 
rather than psychopathology itself, seems to play a role in IBS onset and is one of a group of 
biopsychosocial risk factors which will be more or less significant in different individuals. 
Providing clear information to patients about the pathophysiological link between stress, 
anxiety, depression and the function of the bowel could improve the acceptance of 
behaviourally based treatments to prevent IBS, both amongst health professionals and 
patients. 
Finally, better knowledge of the role of distress in IBS onset may have a positive impact on 
the way clinicians explain the illness to patients when they are diagnosed, improving their 
understanding and acceptance of the condition, especially in those patients who perceive IBS 
as the sole result of psychological factors. 
 
Strengths and limitations 
Several measures were taken to improve the reliability of the systematic processes of this 
meta-analytic review. Firstly, two authors conducted the electronic searches and assessed 
the abstracts and full text articles independently against the inclusion criteria. Secondly, data 
extraction was conducted independently by two authors. Finally, the quality of the studies was 
assessed by two authors and an inter-rater reliability score was calculated.  
We evaluated the methodological quality of the included studies using an adapted version of 
a reliable tool for observational studies. Tailoring the quality assessment tool is advised in the 
Cochrane handbook (Higgins & Green, 2011) to best address the research aims of each 
systematic review. However, we cannot claim that the adapted tool is valid even if the inter-
rater score showed high reliability. Furthermore, we cannot assume that each sub-scale 
contributes a similar weight to the overall quality of the studies.  
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Conclusions  
To our knowledge, this is the first systematic review with meta-analysis that explored the role 
of anxiety and depression in the development of IBS using longitudinal studies with good 
quality designs. The findings suggest that anxious and depressed mood provide a twofold risk 
for the onset of IBS. There is less support for the role of a definitive diagnosis of an anxiety or 
depressive disorder. Although anxiety and depression were found to be risk factors of IBS 
onset, the findings suggest that they are not univariate causes of IBS.  
These findings may have implications for the development of interventions focused on IBS 
prevention and treatment. The role of negative affect should be considered alongside other 
psychological, behavioural and biological factors.
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Legends for figures 
 
 
Figure 1. Flow diagram of systematic literature searches 
 
Figure 2. Forest plot: Anxiety – categorical 
 
Figure 3. Forest plot: Depression – categorical 
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Table 1: characteristics of individual studies 
 
Study Settings  GI Infection N at 
baseline 
Dx IBS at 
baseline 
Time point of 
A/D collection 
A/D categ or 
cont 
Dx IBS at  
follow-ups 
N at follow-ups N IBS+ at  
follow-ups 
Quality 
Assessment 
Gwee et al. 
1996 
Department of 
infectious 
diseases with 
acute GI 
infection, UK. 
Hospitalised 
patients 
 
Different 
pathogens.  
Participants with 
negative stool 
tests included 
86 ROME I. 
Exclusion of 
reported 
organic 
disease 
During infection 
- 1 to 10 days 
after hospital 
admission 
HADS – 
continuous and 
categorical 
(scores of 11 or 
more)  
ROME I 75 out of 86 
(87.21%) at 3 
mths 
22 out of 75 
(29.33%) at 3 
mths 1 
Score=24/29 
 
Category=moder
ate 
Gwee et al. 
1999 
Department of 
infectious 
diseases with 
acute GI 
infection, UK. 
Hospitalised 
patients 
 
Different 
pathogens. 
Participants with 
negative stool 
tests included  
109 ROME I. 
Exclusion of 
reported 
organic 
disease 
During infection 
- 1 to 10 days 
after hospital 
admission 
HADS - 
continuous 
ROME I  94 out of 109 
(86.24%) at 3 
mths 
22 out of 94 
(23.40%) at 3 
mths 
Score=26/29 
 
Category=good 
Moss-Morris 
& Spence, 
2006 
Provider of 
community 
clinical 
diagnostic 
services for 
Auckland, 
New Zealand. 
Primary care 
Campylobacter 835 Self-reported 
history of IBS. 
Exclusion of 
reported 
organic 
disease 
During infection 
or acute phase 
HADS - 
categorical 
(scores of 8 or 
more) 
ROME I updated 
& ROME II 
775 out of 835 
(92.81%) at 3 
mths  
 
748 out of 835 
(89.58%) at 6 
mths 
85 out of 775 at 3 
months (10.97%).  
 
68 out of 748 at 6 
months (9.09%) 
Score=21/29 
 
Category=moder
ate 
Spence & 
Moss-
Morris, 
2007 
Provider of 
community 
clinical 
diagnostic 
services for 
Auckland, 
New Zealand. 
Primary care 
Campylobacter 620 Self-reported 
history of IBS. 
Exclusion of 
reported 
organic 
disease 
During infection 
or acute phase 
HADS - 
continuous   
ROME I updated 
& ROME II 
581 out of 620 at 3 
mths (93.71%) 
 
547 out of 620 at 6 
mths (88.23%) 
 
49 out of 547 
(8.96%) who met 
the criteria both at 
3 and 6-month 
follow-ups  
Score=22/29 
 
Category=moder
ate 
Borgaonkar 
et al. 2006 
Positive stool 
culture from 3 
health regions 
in Ontario, 
Canada  
  
  
  
Different 
pathogens 
191 Manning and 
ROME I. 
Exclusion of 
reported 
organic 
disease 
Mean of 46+-26 
days from the GI 
infection 
HADS - 
continuous 
Manning or 
Rome I 
99 out of 191 
(51.83%) at 3 
mths 
7 out of 99 
(7.07%) at 3 mths 
Score=20/29 
 
Category=moder
ate 
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Parry et al. 
2005 
Northeast 
England. 
Positive 
bacterial stool 
culture from 
the 
microbiology 
laboratories of 
Northumbria 
Healthcare 
Trust 
Different 
pathogens 
122 ROME II. 
Exclusion of 
reported 
organic 
disease 
Participants 
invited within 2 
weeks from the 
stool sample  
HADS - 
categorical 
(scores of 11 or 
more) 
ROME II 107 out of 122 
(87.70%) at 6 
mths 
16 out of the 107 
(14.95%) at 6 
mths 
Score=23/29 
 
Category=moder
ate 
Nielsen et 
al. 2014 
Culture 
positive 
samples from 
North 
Denmark 
region 
Campylobacter 469 Reported 
history of IBS. 
Exclusion of 
reported 
organic 
disease 
Participants 
invited as soon 
after stool 
sample was 
confirmed 
Adapted version 
HADS with 12 
items -  
Categorical 
(scores of 10 or 
more)  
IBS cases were 
identified as 
those reporting 
abdominal pain 
and loose stools, 
in addition to at 
least one of the 
following within 
the last week: 
painful bowel 
movements, 
day-to-day 
variation in stool 
consistency, 
mucous in 
stools, sudden 
bowel 
movements, 
urge for new 
defecation 
shortly after 
defecation, 
flatulence and 
the need to 
loosen clothes 
after meals 
300 out of 469 
(63.97%) at 6 
mths 
 
*Assessment of 
IBS symptoms 
was conducted 
among 268 
(57.14%) 
56 out of 268 
(20.90%) at 6 
mths 
Score=14/29 
 
Category=moder
ate 
Wouters et 
al. 2015 
Community-
wide  
outbreak of 
gastroenteritis 
Different 
pathogens. 
Participants with 
negative stool 
968 ROME III.  
Exclusion of 
reported 
organic 
During infection 
or acute phase 
HADS 
Categorical 
(scores of 11 or 
more) 
Rome III 567 out of 968 
(58.57%) at 1 year 
follow-up 
58 out of 567 
(10.23%) at 1 year 
follow-up 
Score=21/29 
 
Category=moder
ate 
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due to 
contamination 
of tap water 
(Belgium) 
tests included disease 
Talley et al. 
2001 
Longitudinal 
investigation 
of a complete 
cohort 
between April 
1, 1972, and 
March-April, 
2001 
(Dunedin, New 
Zealand) 
No   993 (at 18 
yrs old) 
Not reported Baseline  Modified version 
of the Diagnostic 
Interview 
Schedule  
Rome II and the 
Manning criteria 
992 (99.90%) at 
21 yrs old (3 year 
follow-up) 
 
980 (98.69%) at 
26 yrs  old (8 year 
follow-up) 
ROME II=38 out of 
980 (3.88%) – 8 
yrs follow-up 2 
                        
Manning 
criteria=113 out of 
980 (11.53%) – 8 
yrs follow-up 
Score=20/27 
 
Category=moder
ate 
Nicholl et al. 
2008. 
Population-
based study. 
Registers of 3 
GPs (North 
West England) 
No  5250 Modified 
version of the 
ROME II 
criteria  
Baseline  HADS – 
categorical (3 
categories) 3 
Modified version 
of the ROME II 
criteria 
2456 out of 5250 
(46.78%) at 15 
mths 
86 of 2456 
(3.50%) at 15 
mths 
Score=19/27 
 
Category=moder
ate 
Koloski et 
al. 2012 
Population 
based study, 
electoral roll 
(Penrith, 
Australian)  
No  626 free of 
functional 
disorders at 
baseline 
Slightly 
modified 
version of the 
ROME II 
criteria. 
Exclusion of 
reported 
organic 
disease 
Baseline  Delusion 
Symptom States 
Inventory (DSSI) 
– continuous 
ROME II criteria 1002 out of 1775 
(56.45% of the 
whole sample) at 
12 yrs 
82 cases of IBS 
among the 626 
free of FGID at 
baseline (13.10%) 
at 12 yrs 
Score=19/27 
 
Category=moder
ate 
 
1. The incidence percentages for this review were calculated taking into account the number of participants who developed IBS at the endpoint out of the total number of participants who 
completed the follow-up questionnaire. 
2. This group includes those who met the Manning criteria as well. 
3. They converted the HADS scores into three categories based on the distribution of the participants’ score. 
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Table 2: results of sub-group analyses for both anxiety and depression 
 
Sub-group analysis RR (95% CI) I2 %, p value Comments 
Anxiety    
GI infection studies (Gwee et 
al. 1996; Borgaonkar et al. 
2006; Moss-Morris & Spence, 
2006; Nielsen et al. 2014; 
Wouters et al. 2015) 
 
2.74 (95% CI 1.73-4.34) 66.0%, p=0.019  
No-GI infection studies (Talley 
et al. 2001; Nicholl et al. 2008) 
1.54 (95% CI 0.40-5.88) 87.1%, p=0.005 The two no-GI infection studies had substantial 
differences in their methodology:  
1) Diagnostic criteria - modified clinical structured 
interview schedule vs HADS 
2) Follow-up length - presence of anxiety at 18 or 21 
years old as the predictor of IBS at 26 years old 
(episodic anxiety) vs assessment of anxiety at baseline 
as the predictor of IBS at 15 months  
3) Follow-up response rate - 98.69% vs 46.78% 
HADS (Gwee et al. 1996; 
Moss-Morris & Spence, 2006; 
Nicholl et al. 2008; Wouters et 
al. 2015) 
 
2.90 (95% CI 1.89-4.46) 63.1%, p=0.028 Different cut-offs on HADS to classify anxiety caseness 
may have contributed to the between-study 
heterogeneity 
HADS adapted (Nielsen et al. 
2014) 
 
2.35 (95% CI 1.49-3.72)   
Clinical interview (Talley et al. 
2001) 
0.74 (95% CI 0.31-1.76)   
    
Depression    
GI infection studies (Gwee et 
al. 1996; Parry et al. 2005; 
Borgaonkar et al. 2006; Moss-
Morris & Spence, 2006; 
2.25 (95% CI 1.32-3.83) 58.6%, p=0.034  
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Nielsen et al. 2014; Wouters 
et al. 2015) 
 
No-GI infection studies (Talley 
et al., 2001; Nicholl et al. 
2008) 
1.75 (95% CI 1.05-2.90) 35.7%, p=0.212  
HADS (Gwee et al. 1996; 
Parry et al. 2005; Nicholl et al. 
2008; Moss-Morris & Spence, 
2006; Wouters et al. 2015) 
 
2.23 (95% CI 1.38-3.61) 55.5%, p=0.047 Different cut-offs on HADS to classify depression 
caseness may have contributed to the between-study 
heterogeneity 
HADS adapted (Nielsen et al. 
2014) 
 
2.18 (95% CI 1.22-3.92)   
Clinical interview (Talley et al. 
2001) 
1.22 (95% CI 0.58-2.57)   
 
 
